$KRRO
Korro Bio, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020054017 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2018 Q4
Revenue $11.25M $24.24M $0.00
YoY Change -53.6%
Cost Of Revenue $0.00 $16.00M
YoY Change -100.0%
Gross Profit $11.25M $8.240M
YoY Change 36.53%
Gross Profit Margin 100.03% 34.0%
Selling, General & Admin $6.510M $4.270M $2.400M
YoY Change 52.46% 182.78%
% of Gross Profit 57.87% 51.82%
Research & Development $10.15M $5.221M $2.920M
YoY Change 94.46% 47.07%
% of Gross Profit 90.25% 63.36%
Depreciation & Amortization $301.0K $215.0K $210.0K
YoY Change 40.0% 45.27%
% of Gross Profit 2.68% 2.61%
Operating Expenses $16.67M $25.49M $5.320M
YoY Change -34.62% 404.05%
Operating Profit -$5.418M -$1.252M
YoY Change 332.75% -75.24%
Interest Expense $90.00K $680.0K $150.0K
YoY Change -86.76% 979.37%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.326M -$575.0K -$5.450M
YoY Change 826.26% -88.81%
Income Tax $15.00K
% Of Pretax Income
Net Earnings -$5.341M -$575.0K -$5.447M
YoY Change 828.87% -88.8%
Net Earnings / Revenue -47.49% -2.37%
Basic Earnings Per Share
Diluted Earnings Per Share -$161.5K -$18.62K -$175.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.0M $165.3M
YoY Change 36.75%
Cash & Equivalents $226.0M $142.3M $42.19M
Short-Term Investments $0.00 $23.00M
Other Short-Term Assets $3.100M $307.0K $159.0K
YoY Change 909.77%
Inventory
Prepaid Expenses
Receivables $400.0K
Other Receivables $0.00
Total Short-Term Assets $227.3M $166.7M $42.94M
YoY Change 36.35%
LONG-TERM ASSETS
Property, Plant & Equipment $5.200M $1.566M $1.511M
YoY Change 232.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $101.0K $100.0K
YoY Change 1682.18%
Total Long-Term Assets $7.020M $4.100M $1.611M
YoY Change 71.22%
TOTAL ASSETS
Total Short-Term Assets $227.3M $166.7M $42.94M
Total Long-Term Assets $7.020M $4.100M $1.611M
Total Assets $234.3M $170.8M $44.55M
YoY Change 37.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.089M $3.600M $1.863M
YoY Change 13.58%
Accrued Expenses $4.380M $19.10M $1.749M
YoY Change -77.07%
Deferred Revenue $24.02M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.92M $72.20M
YoY Change -54.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $222.0K $349.0K
YoY Change -100.0%
Other Long-Term Liabilities $1.800M $6.600M
YoY Change -72.73%
Total Long-Term Liabilities $1.800M $222.0K $349.0K
YoY Change 710.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.92M $72.20M
Total Long-Term Liabilities $1.800M $222.0K $349.0K
Total Liabilities $34.73M $82.60M
YoY Change -57.96%
SHAREHOLDERS EQUITY
Retained Earnings -$85.17M -$63.36M -$49.09M
YoY Change 34.43%
Common Stock $34.00K $3.587M $806.0K
YoY Change -99.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.6M $88.30M
YoY Change
Total Liabilities & Shareholders Equity $234.3M $170.8M $44.55M
YoY Change 37.15%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income -$5.341M -$575.0K -$5.447M
YoY Change 828.87% -88.8%
Depreciation, Depletion And Amortization $301.0K $215.0K $210.0K
YoY Change 40.0% 45.27%
Cash From Operating Activities -$10.73M $74.58M -$4.710M
YoY Change -114.39% -2099.46%
INVESTING ACTIVITIES
Capital Expenditures -$1.000M -$150.0K -$240.0K
YoY Change 566.67%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $4.790M
YoY Change -100.42%
Cash From Investing Activities -$1.010M $4.640M -$240.0K
YoY Change -121.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.61M 59.39M 34.87M
YoY Change -31.62% 20379.31%
NET CHANGE
Cash From Operating Activities -10.73M 74.58M -4.710M
Cash From Investing Activities -1.010M 4.640M -240.0K
Cash From Financing Activities 40.61M 59.39M 34.87M
Net Change In Cash 28.87M 138.6M 29.92M
YoY Change -79.17% -4129.36%
FREE CASH FLOW
Cash From Operating Activities -$10.73M $74.58M -$4.710M
Capital Expenditures -$1.000M -$150.0K -$240.0K
Free Cash Flow -$9.730M $74.73M -$4.470M
YoY Change -113.02% -2103.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4089000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Entity File Number
EntityFileNumber
001-39062
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1815000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4380000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24018000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
34000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
284681000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
236161000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
44000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
54000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85167000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68888000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
167358000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234320000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223218000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
165000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33732290
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30844507
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33732290
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30844507
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11247000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24238000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
dei Entity Central Index Key
EntityCentralIndexKey
0001703647
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Frequency Therapeutics, Inc.
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
dei City Area Code
CityAreaCode
866
dei Trading Symbol
TradingSymbol
FREQ
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2324450
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Local Phone Number
LocalPhoneNumber
389-1970
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Address Address Line1
EntityAddressAddressLine1
19 Presidential Way
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12588000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4269000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18720000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5221000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25587000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9837000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
25490000
us-gaap Operating Expenses
OperatingExpenses
44307000
us-gaap Operating Expenses
OperatingExpenses
38425000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1252000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17273000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14187000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
624000
us-gaap Investment Income Interest
InvestmentIncomeInterest
962000
us-gaap Investment Income Interest
InvestmentIncomeInterest
842000
CY2020Q3 us-gaap Liabilities
Liabilities
34728000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
170000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32919000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
180000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2900000
CY2019Q4 us-gaap Liabilities
Liabilities
55860000
CY2020Q3 us-gaap Assets
Assets
234320000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6512000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
161701000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2643000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5326000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5341000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
199592000
CY2019Q3 us-gaap Royalty Expense
RoyaltyExpense
16000000
us-gaap Royalty Expense
RoyaltyExpense
16000000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10153000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
16665000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5418000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
CY2019Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
62000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
65000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
88000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-575000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16219000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13253000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-575000
us-gaap Net Income Loss
NetIncomeLoss
-16279000
us-gaap Net Income Loss
NetIncomeLoss
-13253000
CY2019Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1014000
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1014000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5341000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1589000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16279000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14267000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.17
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33073889
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2163289
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31729702
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1990106
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-34000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
116000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-16000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-34000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13137000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1162000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40143000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-48282000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2456000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
325000
freq Convertible Preferred Stock Issuance Of Dividend
ConvertiblePreferredStockIssuanceOfDividend
1014000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1711000
freq Increase Decrease In Royalties Payable Excluding Accounts Payable
IncreaseDecreaseInRoyaltiesPayableExcludingAccountsPayable
16000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-27034000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
55762000
freq Deferred Lease Incentives
DeferredLeaseIncentives
120000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
116000
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-59652000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
462000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40143000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-16000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-59115000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
925000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
161000
CY2019Q3 freq Convertible Preferred Stock Issuance Of Dividend
ConvertiblePreferredStockIssuanceOfDividend
1014000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-34000
us-gaap Profit Loss
ProfitLoss
-16279000
us-gaap Profit Loss
ProfitLoss
-13253000
us-gaap Share Based Compensation
ShareBasedCompensation
7218000
us-gaap Share Based Compensation
ShareBasedCompensation
2456000
us-gaap Depreciation
Depreciation
760000
us-gaap Depreciation
Depreciation
588000
freq Non Cash Lease Expenses
NonCashLeaseExpenses
256000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25787000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
100085000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-985000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
653000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2870000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
869000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1467000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30355000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
63958000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2253000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
643000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
268818000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
17090000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
245771000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14837000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23690000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1162000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
325000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2461000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
40143000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41305000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59817000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
200259000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42189000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
226046000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142274000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2163000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
24000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
71000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6757125
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p>
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6081000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3828000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2826000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2406
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2066000
CY2020Q3 us-gaap Depreciation
Depreciation
301000
CY2019Q3 us-gaap Depreciation
Depreciation
215000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3057000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2686000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
597000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risks such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5751
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
997
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1766
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.86
CY2018 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16204000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2643000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
925000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7218000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6757125
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26985631
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
CY2019Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.148467
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.7355
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
148724922
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
435000
CY2020Q3 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
714000
CY2019Q4 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
118000
CY2020Q3 freq Accrued Income Taxes And Other Accrued Liabilities Current
AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
12000
CY2019Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.7355
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8524431
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7828326
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.790
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
132683
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
537675
CY2019Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78041
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
297599
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2451
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9964
CY2019Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
669
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2842
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.73
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2456000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
27980000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M9D
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2549000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
308000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2241000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
151000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3311000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4731000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4873000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5020000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
31259000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
49345000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
600000
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12229000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
125000
us-gaap Operating Lease Cost
OperatingLeaseCost
357000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
130000
us-gaap Variable Lease Cost
VariableLeaseCost
328000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
28000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
86000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
153000
us-gaap Operating Lease Expense
OperatingLeaseExpense
443000
us-gaap Operating Lease Payments
OperatingLeasePayments
272000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
135000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
556000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
572000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
590000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
608000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
88000

Files In Submission

Name View Source Status
0001564590-20-054017-index-headers.html Edgar Link pending
0001564590-20-054017-index.html Edgar Link pending
0001564590-20-054017.txt Edgar Link pending
0001564590-20-054017-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
freq-10q_20200930.htm Edgar Link pending
freq-20200930.xml Edgar Link completed
freq-20200930.xsd Edgar Link pending
freq-20200930_cal.xml Edgar Link unprocessable
freq-20200930_def.xml Edgar Link unprocessable
freq-20200930_lab.xml Edgar Link unprocessable
freq-20200930_pre.xml Edgar Link unprocessable
freq-ex311_7.htm Edgar Link pending
freq-ex312_9.htm Edgar Link pending
freq-ex321_142.htm Edgar Link pending
freq-ex321_6.htm Edgar Link pending
freq-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending